Respiratory viruses and virus-like particle vaccine development: how far have we advanced?

KB Chu, FS Quan - Viruses, 2023 - mdpi.com
With technological advancements enabling globalization, the intercontinental transmission
of pathogens has become much easier. Respiratory viruses are one such group of …

Current Progress, Challenges and Prospects in the Development of COVID-19 Vaccines

C Zhu, S Pang, J Liu, Q Duan - Drugs, 2024 - Springer
The COVID-19 pandemic has resulted in over 772 million confirmed cases, including nearly
7 million deaths, according to the World Health Organization (WHO). Leveraging rapid …

From co-administration to co-formulation: the race for new vaccines against COVID-19 and other respiratory viruses

D Focosi - Vaccines, 2023 - mdpi.com
Vaccines | Free Full-Text | From Co-Administration to Co-Formulation: The Race for New
Vaccines against COVID-19 and Other Respiratory Viruses Next Article in Journal Indian …

A multi-antigen vaccinia vaccine broadly protected mice against SARS-CoV-2 and influenza A virus while also targeting SARS-CoV-1 and MERS-CoV

N Gao, T Yang, L Dong, W Tang, K Cao… - Frontiers in …, 2024 - frontiersin.org
Introduction Coronaviruses and influenza viruses are significant respiratory pathogens that
cause severe disease burdens and economic losses for society. Due to their diversity and …

[HTML][HTML] SARS-CoV-2 spike-based virus-like particles incorporate influenza H1/N1 antigens and induce dual immunity in mice

ZV Sanchez-Martinez, SP Alpuche-Lazcano, M Stuible… - Vaccine, 2024 - Elsevier
A vaccine effective against both SARS-CoV-2 and influenza A (IAV) viruses could represent
a cost-effective strategy to reduce their combined public health burden as well as potential …

Expression of the SARS-CoV-2 receptor-binding domain by live attenuated influenza vaccine virus as a strategy for designing a bivalent vaccine against COVID-19 …

E Stepanova, I Isakova-Sivak, D Mezhenskaya… - Virology Journal, 2024 - Springer
Influenza and SARS-CoV-2 are two major respiratory pathogens that cocirculate in humans
and cause serious illness with the potential to exacerbate disease in the event of co …

[HTML][HTML] Safety, Immunogenicity and Protective Activity of a Modified Trivalent Live Attenuated Influenza Vaccine for Combined Protection Against Seasonal Influenza …

E Stepanova, V Matyushenko, D Mezhenskaya… - Vaccines, 2024 - pmc.ncbi.nlm.nih.gov
Background/Objectives: Influenza viruses and SARS-CoV-2 are currently cocirculating with
similar seasonality, and both pathogens are characterized by a high mutational rate which …

Multivalent and Sequential Heterologous Spike Protein Vaccinations Effectively Induce Protective Humoral Immunity against SARS-CoV-2 Variants

R Liu, JP Natekar, KH Kim, H Pathak, N Bhatnagar… - Vaccines, 2024 - mdpi.com
The emergence of new SARS-CoV-2 variants continues to cause challenging problems for
the effective control of COVID-19. In this study, we tested the hypothesis of whether a …

Towards broad-spectrum protection: the development and challenges of combined respiratory virus vaccines

Y Wang, X Wei, Y Liu, S Li, W Pan, J Dai… - Frontiers in Cellular and …, 2024 - frontiersin.org
In the post-COVID-19 era, the co-circulation of respiratory viruses, including influenza, SARS-
CoV-2, and respiratory syncytial virus (RSV), continues to have significant health impacts …

Hemagglutinin virus-like particles incorporated with membrane-bound cytokine adjuvants provide protection against homologous and heterologous influenza virus …

BR Park, R Bommireddy, DH Chung, KH Kim… - Immunity & …, 2023 - Springer
Background Current influenza vaccines deliver satisfactory results in young people but are
less effective in the elderly. Development of vaccines for an ever-increasing aging …